Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC lifted its position in Annexon, Inc. (NASDAQ:ANNX - Free Report) by 18.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,143,635 shares of the company's stock after purchasing an additional 331,269 shares during the period. Geode Capital Management LLC owned 2.03% of Annexon worth $12,693,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Parkman Healthcare Partners LLC lifted its holdings in shares of Annexon by 0.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 328,613 shares of the company's stock worth $1,945,000 after buying an additional 1,768 shares during the period. The Manufacturers Life Insurance Company lifted its stake in Annexon by 1.6% in the third quarter. The Manufacturers Life Insurance Company now owns 159,586 shares of the company's stock worth $945,000 after acquiring an additional 2,450 shares during the period. GSA Capital Partners LLP grew its holdings in Annexon by 10.7% during the 3rd quarter. GSA Capital Partners LLP now owns 34,581 shares of the company's stock worth $205,000 after acquiring an additional 3,355 shares in the last quarter. Allegheny Financial Group LTD increased its position in Annexon by 16.1% during the 2nd quarter. Allegheny Financial Group LTD now owns 25,200 shares of the company's stock valued at $123,000 after purchasing an additional 3,500 shares during the period. Finally, MetLife Investment Management LLC raised its holdings in shares of Annexon by 11.8% in the 3rd quarter. MetLife Investment Management LLC now owns 55,212 shares of the company's stock valued at $327,000 after purchasing an additional 5,814 shares in the last quarter.

Wall Street Analysts Forecast Growth

ANNX has been the topic of a number of recent research reports. Needham & Company LLC reiterated a "buy" rating and set a $16.00 price objective on shares of Annexon in a research note on Friday, November 15th. HC Wainwright reiterated a "buy" rating and issued a $30.00 price target on shares of Annexon in a report on Tuesday, December 17th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Annexon in a research note on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $15.80.

Insider Transactions at Annexon

In other news, EVP Ted Yednock sold 5,408 shares of the company's stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $7.41, for a total transaction of $40,073.28. Following the transaction, the executive vice president now owns 71,365 shares in the company, valued at $528,814.65. This represents a 7.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 12.67% of the company's stock.

Annexon Stock Performance

NASDAQ ANNX remained flat at $5.13 on Tuesday. 1,039,359 shares of the company's stock traded hands, compared to its average volume of 1,776,754. The business has a 50-day moving average of $5.85 and a two-hundred day moving average of $5.94. The company has a market capitalization of $546.83 million, a PE ratio of -4.89 and a beta of 1.10. Annexon, Inc. has a fifty-two week low of $3.86 and a fifty-two week high of $8.40.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.